EVP, Head of R&D & CMO · Travere Therapeutics, Inc. · Common Stock
Side
M
Value
$289K
Shares
32.4K
Price
$8.93
Executed
Sep 15, 2026
Disclosed
Sep 17, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Sep 15 executedSep 17, 2026 disclosed
TVTX · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+15 / 25
$289K reported value · 28.7% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+1 / 15
Routine: 10 prior trades recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Inrig Jula filed this Form 4 reporting a option exercise of TVTX on Sep 15, 2026. It became public on Sep 17, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
EVP, Head of R&D & CMO
Inrig Julacik:0001902368
Issuer
Travere Therapeutics, Inc.cik:0001438533
Revision history · 0
No field has changed since this record was first ingested.
